(NASDAQ:NEOG) is preparing to release its third-quarter earnings on April 9, 2026. Known for its food and animal safety products, Neogen operates in a competitive market alongside companies like Zoetis. Analysts expect earnings per share (EPS) to be $0.04, a significant drop from last year's $0.10.
Revenue projections for Neogen are around $204.5 million, slightly below the $204.62 million anticipated by analysts. This marks a 7.5% decrease from the previous year's $220.98 million. Such declines can impact investor sentiment and stock performance.
The recent sale of Neogen's Genomics business to Zoetis led to a 1.6% increase in share price, closing at $9.56. This strategic move might influence future earnings and market positioning. Piper Sandler's David Westenberg maintained a Neutral rating, raising the price target to $10.
Neogen's financial health shows a debt-to-equity ratio of 0.38, indicating moderate debt levels. Its current ratio of 3.91 reflects strong liquidity, suggesting the company can comfortably meet short-term obligations. These metrics are crucial for assessing financial stability.
The upcoming earnings report is pivotal. If Neogen surpasses expectations, the stock could rise. However, missing targets might lead to a decline. Management's insights during the earnings call will be key in shaping future expectations and stock performance.
